Natera, Inc. ($NTRA) Stock Forecast: Up 7.1% Today

What is Natera, Inc.?

Natera, Inc. (NTRA) is a leading biotechnology company specializing in genetic testing and molecular diagnostics. The company focuses on developing innovative solutions for various medical conditions, including cancer and prenatal testing. The stock had a strong bullish movement today.

Why is Natera, Inc. going up?

NTRA stock is up 7.1% on May 29, 2026 13:56

• The bullish movement in Natera's stock could be attributed to the positive market reception of its collaboration with Diakonos Oncology Corp. for a Phase I/II trial in refractory melanoma using the Signatera test. This partnership aims to provide early insights into treatment response dynamics, which is a significant development in the field of personalized medicine.
• The recent sale of shares by the company's executives to cover tax obligations may have initially caused some uncertainty among investors. However, the market seems to have focused more on the promising collaboration and the potential impact on cancer treatment.
• Natera's announcement of an enhanced Panorama non-invasive prenatal test (NIPT) could also have contributed to the positive sentiment, showcasing the company's continued efforts in advancing its genetic testing portfolio and addressing medical needs across different areas.
• Overall, the market's bullish reaction to Natera's strategic collaborations and product enhancements reflects investor confidence in the company's growth prospects and its commitment to driving innovation in genetic testing and personalized medicine.

NTRA Price Chart

NTRA Technical Analysis

NTRA News

Natera partners with Diakonos for melanoma therapy trial

Natera Inc. announced a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma using Natera's Signatera test. This partnership will support Diakonos' DOC-RM Phase I/II trial for DOC1021, an investigational personalized dendritic cell therapy, by analyzing circulating tumor DNA. Natera believes serial ctDNA monitoring can offer earlier insights into treatment response compared to traditional radiographic assessments.

https://www.investing.com/news/company-news/natera-partners-with-diakonos-for-melanoma-therapy-trial-93CH-4716301

Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma

Natera, Inc. announced a collaboration with Diakonos Oncology Corp. to use Signatera™ in a Phase I/II trial for patients with refractory melanoma. Signatera will assess molecular response to Diakonos’ investigational dendritic cell therapy, DOC1021, which recently received FDA Fast Track designation. This partnership aims to provide early insights into treatment response dynamics in a challenging cancer where traditional imaging often lags biological changes.

https://sg.finance.yahoo.com/news/natera-announces-collaboration-diakonos-oncology-100000652.html

Natera (NTRA) president sells 1,652 shares to cover RSU tax obligations

Natera, Inc.'s president of clinical diagnostics, Solomon Moshkevich, sold 1,652 shares of common stock for over $335,000 at a price of $202.8398 per share. This transaction was conducted to fulfill tax withholding obligations related to RSU vesting and was executed under a Rule 10b5-1(c) plan. After the sale, Moshkevich directly holds 140,643 shares in the company.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-d2b53ddc53e5.html

Natera (NTRA) president sells 1,438 shares to cover RSU tax withholding

John Fesko, President and Chief Business Officer of Natera, Inc. (NTRA), sold 1,438 shares of the company's common stock at an average price of $202.8398 per share. This transaction was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs) and was executed under a pre-arranged 10b5-1 trading plan. Following the sale, Fesko directly holds 185,782 shares of Natera common stock.

https://www.stocktitan.net/sec-filings/NTRA/form-4-natera-inc-insider-trading-activity-21c7125d2406.html

Natera to Launch Enhanced Panorama NIPT for Low Fetal Fractions

Natera (NTRA) has announced an enhanced Panorama non-invasive prenatal test (NIPT) that

https://www.theglobeandmail.com/investing/markets/stocks/NTRA/pressreleases/2181065/natera-to-launch-enhanced-panorama-nipt-for-low-fetal-fractions/

Trending Today

Cadence Design Systems Inc. ($CDNS) Stock Forecast: Up 5.1% Today

Interactive Brokers Group, Inc. ($IBKR) Stock Forecast: Up 5.6% Today

Oracle Corporation ($ORCL) Stock Forecast: Up 6.4% Today

Abbott Laboratories ($ABT) Stock Forecast: Up 0.8% Today

Upwork Inc. ($UPWK) Stock Forecast: Up 5.0% Today

Coinbase Global Inc. ($COIN) Stock Forecast: Up 5.2% Today

Lyft Inc. ($LYFT) Stock Forecast: Up 5.0% Today

Rivian Automotive Inc. ($RIVN) Stock Forecast: Up 5.2% Today

International Business Machines Corporation ($IBM) Stock Forecast: Up 5.3% Today

Pinterest Inc. Class A ($PINS) Stock Forecast: Up 5.5% Today

Natera, Inc. Price History

08.04.2026 - NTRA Stock was down 7.7%

• Despite strong revenue growth driven by successful products like Fetal Focus and Signatera MRD test, Natera faced a bearish movement in its stock, potentially linked to a wider net loss reported in the same quarter, raising concerns about profitability.
• The missed EPS estimate and increased operating expenses leading to a higher net loss are likely factors contributing to the negative market sentiment towards Natera.
• Investors may be concentrating on the company's ability to manage expenses and bottom line performance, somewhat overshadowing the positive revenue growth and raised revenue guidance for the full year.
• The market's response could also be influenced by the stock's recent underperformance compared to the broader market, despite surpassing revenue expectations, suggesting a possible mismatch in investor expectations and market valuation.

15.04.2026 - NTRA Stock was down 5.3%

• Natera's stock experienced a strong bearish movement of 5.9% today.
• The market reacted negatively to Natera's Q1 2026 earnings report despite raising its 2026 revenue and gross margin guidance. This can be attributed to the wider net loss of US$85.09 million due to increased operating expenses for clinical trials, new products, and international expansion.
• Cathie Wood's ARK Invest's strategic shift towards increasing its stake in Natera while selling shares in other biotech companies may have also influenced market sentiment, signaling a shift in focus within the biotech sector.
• Analysts' mixed reactions to Natera's first-quarter results, with revenue beating expectations but statutory losses being larger than forecast, could have added to the overall bearish sentiment surrounding the stock.

20.04.2026 - NTRA Stock was up 5.1%

• The FDA's approval of Natera's Signatera CDx blood test as a companion diagnostic for muscle-invasive bladder cancer has led to a surge in the company's stock performance.
• This approval underscores the importance of MRD testing as a critical tool in clinical decision-making, potentially boosting revenue projections for Natera.
• Despite these positive developments, investors are advised to be wary of Natera's high expenditures, ongoing financial losses, as well as legal and regulatory challenges that could affect its future growth prospects.
• Despite recent declines in the stock price, Natera's robust revenue growth and optimistic analyst outlook suggest that the company may be undervalued, offering investors an opportunity to consider a bullish stance on Natera for the long term.

29.04.2026 - NTRA Stock was up 7.1%

• The bullish movement in Natera's stock could be attributed to the positive market reception of its collaboration with Diakonos Oncology Corp. for a Phase I/II trial in refractory melanoma using the Signatera test. This partnership aims to provide early insights into treatment response dynamics, which is a significant development in the field of personalized medicine.
• The recent sale of shares by the company's executives to cover tax obligations may have initially caused some uncertainty among investors. However, the market seems to have focused more on the promising collaboration and the potential impact on cancer treatment.
• Natera's announcement of an enhanced Panorama non-invasive prenatal test (NIPT) could also have contributed to the positive sentiment, showcasing the company's continued efforts in advancing its genetic testing portfolio and addressing medical needs across different areas.
• Overall, the market's bullish reaction to Natera's strategic collaborations and product enhancements reflects investor confidence in the company's growth prospects and its commitment to driving innovation in genetic testing and personalized medicine.

17.03.2026 - NTRA Stock was up 5.1%

• Natera (NTRA) reported impressive fourth-quarter results, exceeding earnings and revenue estimates, which likely boosted investor confidence in the company's performance.
• Positive interim futility analysis from Allogene Therapeutics' ALPHA3 trial, utilizing Natera's CLARITY™ MRD assay, showcased the effectiveness of Natera's technology in identifying high-risk patients and potentially preventing relapse in large B-cell lymphoma cases.
• Despite holding a Zacks Rank #4 (Sell) due to estimate revisions, the initiation of coverage by William Blair with an "outperform" recommendation highlighted Natera's strong position in the growing MRD testing market, projecting significant revenue growth potential.
• The mixed share price performance evaluation, indicating undervaluation by DCF model but overvaluation by P/S ratio, suggests varying perspectives on Natera's future valuation and growth prospects, leaving investors with contrasting views on the stock's true value.

23.03.2026 - NTRA Stock was down 5.2%

• The recent bearish movement in Natera's stock could be attributed to:
• Profit-taking by insiders: Co-founder Sheena Jonathan and family trusts selling a significant number of shares could have indicated a lack of confidence in the short-term performance of the stock.
• Overvaluation concerns: Despite the recent price surge, valuation metrics like the Price-to-Sales (P/S) ratio suggesting overvaluation might have led investors to capitalize on their gains.
• Market dynamics: While Natera's stock experienced a downward trend, other companies in the healthcare sector, such as UFP Technologies, Mettler-Toledo, and Viatris, saw substantial gains, potentially diverting investor attention away from Natera.
• Overall market sentiment: The reopening of the Strait of Hormuz resulting in decreased logistics and energy costs may have redirected investor focus to companies directly benefiting from these changes, impacting Natera's stock negatively.

06.04.2026 - NTRA Stock was up 5.1%

• The bullish movement in Natera's stock today is linked to positive developments such as an "Outperform" rating from William Blair, a patent victory, and promising study results for its Signatera assay.
• The selling of shares by key executives like Sheena Jonathan, John Fesko, and CEO Steven Chapman to cover tax obligations initially raised concerns. However, these pre-arranged transactions, in light of positive news, likely reassured investors about the company's health and future prospects.
• Strategic selling of shares by company insiders under Rule 10b5-1 plans, despite the stock being down year-to-date, may indicate a prudent approach to finance management while maintaining confidence in company performance.
• The combination of positive company developments and strategic insider selling likely fueled the bullish movement in Natera's stock today, demonstrating a blend of financial responsibility and investor confidence in the company's growth trajectory.

30.03.2026 - NTRA Stock was up 5.1%

• The company revealed its first-quarter financial results and held a conference call, potentially boosting investor confidence and fueling the bullish movement.
• Insider selling by the co-founder and CEO, aimed at covering tax obligations, initially raised concerns but a clarified context of these sales being part of a pre-arranged trading plan may have alleviated any negative impact.
• Despite Natera's current lack of profitability, positive court rulings and new analyst coverage could have positively influenced investor sentiment, contributing to the bullish market performance.
• Taken together, positive updates on financial results, structured insider trading activities, and external factors like court decisions and analyst coverage likely played a role in Natera's recent strong bullish trend.

28.04.2026 - NTRA Stock was up 5.1%

• Today's bullish movement in Natera's stock is likely linked to positive updates on its clinical trials and innovations in genetic testing technologies.
• Commencement of patient enrollment for early-stage breast cancer studies and progress in trials for breast cancer and bladder cancer treatments have contributed to increased investor confidence.
• Upgrades to the Panorama prenatal test and FDA approval for Signatera in bladder cancer demonstrate Natera's dedication to innovation and expanding its market reach.
• Despite concerns regarding insider selling and valuation risks, the favorable outcomes in Natera's clinical trials and testing capabilities appear to have had a stronger impact, resulting in an upsurge in the stock price.

29.03.2026 - NTRA Stock was down 5.0%

• The downward trend in Natera's stock price could be linked to notable insider selling activity by directors such as Roelof Botha, Eric H. Rubin, and Ruth Williams Brinkley. This activity may have sparked concerns among investors regarding the company's future outlook.
• Despite the release of positive information regarding Natera's recent clinical evidence for its Prospera transplant test, which could potentially boost revenue, the overall market sentiment may have been clouded by the insider selling, as well as the company's negative net margins and ROE.
• While the initial increase in M&T Bank Corp's stake could have been viewed as a positive development, investor focus appeared to shift towards the insider selling and the company's financial difficulties, contributing to today's bearish movement in the stock.

08.04.2026 - NTRA Stock was down 6.0%

• Natera's strong revenue growth and milestone of processing over 1 million tests in a quarter showcased its continued expansion and market demand for its services.
• The wider loss per share than expected could have contributed to the bearish movement in the stock, despite positive revenue performance.
• The sale of shares by the Executive Chairman to cover tax obligations may have also impacted investor sentiment, leading to a decline in the stock price.
• Overall, while Natera's operational performance remains robust, market reaction to the earnings miss and insider selling likely drove the bearish movement in the stock today.

11.04.2026 - NTRA Stock was up 5.1%

• Despite concerns over its high valuation influencing a decline in stock price, Natera's impressive Q1 earnings call, demonstrating revenue growth and increased volume, has boosted investor confidence.
• Analysts have raised the 12-month price target to $260.78, indicating a 19% potential upside, reflecting optimism regarding Natera's future performance.
• The unexpected Q4 profit of US$47.3 million has shifted focus from prior losses to potential growth, although discussions on the stock's valuation persist among investors.
• Analysts' continued Buy rating and optimistic outlook, with target prices spanning from $136 to $285, further bolster the positive trajectory of Natera's stock.